April 30, 2022
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
First novel, nonstimulant option for adults with ADHD in 20 yearsADHD affects an estimated 10 million adults in the U.S.…
Pharmaceuticals, Biotechnology and Life Sciences
First novel, nonstimulant option for adults with ADHD in 20 yearsADHD affects an estimated 10 million adults in the U.S.…
ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in EuropeMyovant expects to secure…
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge,…
MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”) (NASDAQ: TELA), a commercial-stage medical technology company focused…
BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”),…
Lille, France; Cambridge, MA; April 29, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving…
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, April 29, 2022 (GLOBE…
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by…
FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update.…
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing…